Radiation Therapy Are Not Effective Mesothelioma Patients, However Gene Therapy Offers a Hope
Oncologists and other cancer doctors decide what type of treatment to administer with a patient. The options are endless. There exists no one size fits all treatment course for peritoneal mesothelioma sufferers. Mesotheliomas lack of agreed-upon treatment is due to low a treatment success rate, rareness, a high mortality rate and a small number of studies providing meaningful stats.
While prospects for patients with mesothelioma have been bleak, doctors have been making progress. Treatments for cancer are traditionally surgery (taking out the tumor and surrounding tissue), chemotherapy (poisoning cancerous cells) and radiation (killing cancer cells with radiation) There are problems with all three. Traditional radiation therapy has not worked well with mesothelioma patients. Researches, concerned about damage to healthy tissue, are looking for ways to aim radiation directly at tumors.
Surgery removes the mesothelial tissue around the tumor. The surgery is difficult and challenging, with unknown effects or benefits to patients. The usual chemotherapy cocktails effective on other cancers are not effective on mesothelioma, and different combinations of chemotherapy drugs have been tried without a lot of success. Like radiation, researchers are focusing their work on controlling the physical location of the treatment with an emphasis on the pleural cavity.
The death rate for mesothelioma is so high that many of even the most sophisticated techniques in cancer treatment are tried out on patients. These techniques include a biologic therapy called the agent interleukin 2 and anti-angiogenesis drugs like thalidomide. The new drug pemetrexed (brand name Alimta) has shown good results in extending life with mesotheliomas..
Oncologists consider the stage of mesothelioma, the location of the tumor, the patient’s age and state of health at the time. Two exotic ways of attacking mesothelioma are gene therapy and photodynamic therapy. Patients afflicted with mesothelioma are benefitting in these clinical trials.
